# The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients

Study · id `cardio:ct-nct04365517` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04365517](<https://clinicaltrials.gov/study/NCT04365517>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04365517

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.

## Technical summary

Registry record NCT04365517. Randomized; no masking; primary purpose treatment. Start 2021-12-29 (anticipated); primary completion 2022-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT04365517, source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)
- Planned start: 2021-12-29 (anticipated) (ClinicalTrials.gov record NCT04365517, source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)
- Primary completion: 2022-03-30 (anticipated) (ClinicalTrials.gov record NCT04365517, source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT04365517, source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT04365517, source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04365517-2021-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
- Acronym: SIDIACO
- Condition: Covid19
- Condition: Diabetes Mellitus, Type 2
- Condition: CKD
- Intervention (Drug): Sitagliptin
- Lead sponsor: University of Milan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Milan (`cardio:org-university-of-milan`)

## Provenance

Content hash: 665ead11adc3390424b1cbedabd475e0eea679bf663bf275cfac6f1f177092b1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
